Integra LifeSciences Holdings Corporation $IART Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 9.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,146,921 shares of the life sciences company’s stock after acquiring an additional 99,348 shares during the period. Charles Schwab Investment Management Inc. owned about 1.48% of Integra LifeSciences worth $25,221,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IART. Sterling Capital Management LLC grew its holdings in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after acquiring an additional 1,931 shares during the period. CWM LLC grew its holdings in Integra LifeSciences by 413.8% in the first quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock valued at $147,000 after purchasing an additional 5,367 shares during the period. Teacher Retirement System of Texas acquired a new stake in Integra LifeSciences in the first quarter valued at approximately $223,000. NorthRock Partners LLC acquired a new stake in Integra LifeSciences in the fourth quarter valued at approximately $251,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Integra LifeSciences in the first quarter valued at approximately $251,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $14.26 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The business’s 50 day moving average price is $12.70 and its 200-day moving average price is $16.62. The firm has a market capitalization of $1.11 billion, a PE ratio of -2.18, a P/E/G ratio of 0.83 and a beta of 1.16. Integra LifeSciences Holdings Corporation has a 1 year low of $11.06 and a 1 year high of $27.13.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The firm had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The business’s revenue was down .6% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. As a group, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on IART. Wells Fargo & Company dropped their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price objective on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating on the stock in a report on Friday, May 9th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $18.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.